news2026-08-29T10:00:51+00:00Landmark approval for pancreatic cancer; Reactions to Lilly’s Phase 1 secrecy; and more
news2026-08-29T06:55:35+00:00#ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo’s failure
